Related Experiment Video
Updated: May 19, 2026

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
Published on: May 19, 2020
Non-Adherence to Anti-Tuberculosis Treatment and Its Determinants Among Tuberculosis Patients in Tanzania
Meshack Morice1, Bernadetha Hugho Kimario2, Indo Ndaigeze2
1Community Medicine, Kairuki University, P.O. Box 65300, Dar es Salaam, Tanzania. meshack.morice@ku.ac.tz.
Abstract:
Non-adherence to anti-tuberculosis (TB) treatment remains a major barrier to effective TB control, contributing to poor treatment outcomes, relapse, and the emergence of drug-resistant TB. Evidence on the magnitude and determinants of non-adherence in Tanzania is limited. This study assessed the prevalence of non-adherence to anti-TB treatment and its associated factors. A hospital-based cross-sectional study was conducted among adult TB patients receiving treatment at Mwananyamala Regional Referral Hospital. 245 participants were recruited using systematic random sampling. Data were collected using a structured interviewer-administered questionnaire. Descriptive statistics were used to summarize participant characteristics. Log-binomial regression analysis was performed to estimate crude and adjusted prevalence ratios (PRs) with 95% confidence intervals (CIs) for factors associated with non-adherence, with significance set at p < 0.05. The prevalence of anti-TB non-adherence was 33.5%. Experiencing side effects (aPR = 1.664; 95% CI: 1.129-2.449) and poor knowledge about TB (aPR = 1.704; 95% CI: 1.062-2.732) were associated with increased likelihood of non-adherence. Family support was associated with a lower likelihood of non-adherence (aPR = 0.696; 95% CI: 0.487-0.994). Other socio-demographic, clinical, and health system factors were not significantly associated with non-adherence. Non-adherence to anti-TB treatment remains high in Tanzania, affecting approximately one-third of patients. Medication side effects and poor TB knowledge are key drivers of non-adherence, while family support plays a protective role. Interventions focusing on patient education, effective management of treatment side effects, and strengthening family and community support systems are essential to improve adherence and enhance TB control efforts.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Therapeutic Drug Monitoring: Affecting Factors
